




The relative strengths and weaknesses of Ernexa Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Ernexa Therapeutics Inc compared to the market average is the variable Revenues, increasing the Economic Capital Ratio by 74% points. The greatest weakness of Ernexa Therapeutics Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 143% points.

The company's Economic Capital Ratio, given in the ranking table, is 213%, being 25% points below the market average of 238%.

Input Variable	Value in 1000 USD
Assets, Current	6,070
Cost of Goods Sold	0
Intangible Assets	696
Liabilities, Current	6,095
Liabilities, Non-Current	2,917
Other Assets	4,537
Other Compr. Net Income	68
Other Expenses	8,420
Other Liabilities	22
Other Net Income	-258
Other Revenues	19,806
Property and Equipment	2,822
Research and Development	0
Selling, General and Administrative Expense	13,175

Output Variable	Value in 1000 USD
Assets	14,125
Liabilities	9,034
Expenses	21,595
Revenues	19,806
Stockholders Equity	5,091
Net Income	-2,047
Comprehensive Net Income	-2,013
BaseVar	32,443
ECR before Limited Liability	78%
Economic Capital Ratio	213%